INCY Latest Press Releases

-- December 8, 2025 --

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia Business Wire 4:30 PM

-- December 7, 2025 --

Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA Business Wire 9:30 AM

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 Business Wire 9:30 AM

-- December 3, 2025 --

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- December 2, 2025 --

Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding Business Wire 9:15 AM

-- December 1, 2025 --

Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel Business Wire 8:00 AM

-- November 19, 2025 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- November 17, 2025 --

Incyte Announces Positive CHMP Opinion for Minjuvi (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) Business Wire 1:00 AM

-- November 6, 2025 --

Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema Business Wire 9:15 AM

-- November 4, 2025 --

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors Globe Newswire 7:01 AM

-- November 3, 2025 --

Incyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting Business Wire 9:31 AM

-- October 30, 2025 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

Knight Therapeutics Announces Approval and Launch of MINJUVI (tafasitamab) in Argentina Globe Newswire 7:30 AM

-- October 28, 2025 --

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates Business Wire 7:00 AM

-- October 27, 2025 --

Incyte and Enable Injections Announce Strategic Partnership for enFuse On-Body Delivery System Business Wire 7:30 AM

-- October 25, 2025 --

Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis Business Wire 7:55 PM

-- October 24, 2025 --

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial PRNewswire 6:45 AM

-- October 19, 2025 --

Incyte Announces Phase 1 Results for its TGFR2PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma Business Wire 1:30 PM

-- October 12, 2025 --

Data from Incyte's TGFR2PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025 Business Wire 6:05 PM

-- October 8, 2025 --

Incyte to Report Third Quarter Financial Results Business Wire 8:00 AM

-- September 28, 2025 --

China Medical System (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication Globe Newswire 12:20 AM

-- September 24, 2025 --

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:30 PM

-- September 22, 2025 --

Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer Business Wire 7:30 AM

-- September 18, 2025 --

Incyte Announces Additional FDA Approval of Opzelura (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis Business Wire 4:21 PM

-- September 17, 2025 --

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025 Business Wire 1:00 AM

-- September 10, 2025 --

Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress Business Wire 7:30 AM

-- September 3, 2025 --

Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa Business Wire 9:15 AM

-- August 27, 2025 --

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:15 PM

-- August 25, 2025 --

Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer Business Wire 8:00 AM

-- August 19, 2025 --

Incyte to Present at Upcoming Investor Conferences Business Wire 8:00 AM

-- August 5, 2025 --

Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis Business Wire 4:05 PM

-- August 4, 2025 --

Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America Globe Newswire 4:30 PM

-- July 31, 2025 --

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI (tafasitamab) for Follicular Lymphoma in Brazil Globe Newswire 4:30 PM

-- July 29, 2025 --

Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire 7:00 AM

-- July 24, 2025 --

Incyte To Present Initial Data for its TGFR2PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025 Business Wire 5:02 PM

-- July 10, 2025 --

Incyte to Report Second Quarter Financial Results Business Wire 8:00 AM